This cross-sectional study aims to determine the prevalence of pulmonary hypertension and right ventricular dysfunction in patients with myeloproliferative neoplasms and to identify associated clinical and hematologic factors.
Myeloproliferative neoplasms (MPNs) are associated with an increased risk of pulmonary hypertension and right ventricular dysfunction. This observational study will include adults with confirmed polycythemia vera, essential thrombocythemia, or primary myelofibrosis. All participants will undergo clinical assessment, laboratory evaluation, and echocardiography to assess pulmonary artery systolic pressure and right ventricular systolic function (TAPSE, FAC, and tissue Doppler S').
Study Type
OBSERVATIONAL
Enrollment
145
Prevalence of Pulmonary Hypertension in MPN Patients
PASP measured by echocardiography using TR velocity. Pulmonary hypertension defined as PASP greater than 35 mmHg or TR velocity greater than 2.8 m/s. Prevalence will be calculated.
Time frame: Baseline
Prevalence of right ventricular dysfunction
Proportion of patients with right ventricular dysfunction defined by TAPSE \<17 mm, RV fractional area change \<35%, or tissue Doppler S' \<9.5 cm/s
Time frame: Baseline
Pulmonary artery systolic pressure
Mean estimated pulmonary artery systolic pressure (mmHg) measured by echocardiography
Time frame: Baseline
Tricuspid annular plane systolic excursion (TAPSE)
Mean TAPSE value (mm) measured by echocardiography.
Time frame: Baseline
Right ventricular fractional area change
Mean right ventricular fractional area change (%) measured by echocardiography.
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.